1 Department of Pharmacology and Therapeutics, and.
2 Lung Health Research Centre, The University of Melbourne, Parkville, Victoria, Australia.
Am J Respir Cell Mol Biol. 2018 Sep;59(3):375-382. doi: 10.1165/rcmb.2017-0188OC.
Primary ciliary dyskinesia is an inherited, currently incurable condition. In the respiratory system, primary ciliary dyskinesia causes impaired functioning of the mucociliary escalator, leading to nasal congestion, cough, and recurrent otitis media, and commonly progresses to cause more serious and permanent damage, including hearing deficits, chronic sinusitis, and bronchiectasis. New treatment options for the condition are thus necessary. In characterizing an immortalized human bronchial epithelial cell line (BCi-NS1.1) grown at an air-liquid interface to permit differentiation, we have identified that these cells have dyskinetic motile cilia. The cells had a normal male karyotype, and phenotypic markers of epithelial cell differentiation emerged, as previously shown. Ciliary beat frequency (CBF) as assessed by high-speed videomicroscopy was lower than normal (4.4 Hz). Although changes in CBF induced by known modulators were as expected, the cilia displayed a dyskinetic, circular beat pattern characteristic of central microtubular agenesis with outer doublet transposition. This ultrastructural defect was confirmed by electron microscopy. We propose that the BCi-NS1.1 cell line is a useful model system for examination of modulators of CBF and more specifically could be used to screen for novel drugs with the ability to enhance CBF and perhaps repair a dyskinetic ciliary beat pattern.
原发性纤毛运动障碍是一种遗传性疾病,目前尚无治愈方法。在呼吸系统中,原发性纤毛运动障碍会导致黏液纤毛清除功能受损,引起鼻塞、咳嗽和复发性中耳炎,并常进展为更严重和永久性的损害,包括听力损失、慢性鼻窦炎和支气管扩张。因此,需要新的治疗选择。在对在气液界面生长以促进分化的永生化人支气管上皮细胞系(BCi-NS1.1)进行特征描述时,我们发现这些细胞的运动纤毛存在动力障碍。如前所述,这些细胞具有正常的男性核型和上皮细胞分化的表型标志物。通过高速视频显微镜评估的纤毛摆动频率(CBF)低于正常水平(4.4 Hz)。尽管已知调节剂引起的 CBF 变化符合预期,但纤毛显示出一种动力障碍的圆形摆动模式,这是中央微管缺失伴外二联体易位的特征。这种超微结构缺陷通过电子显微镜得到了证实。我们提出,BCi-NS1.1 细胞系是一个有用的模型系统,可用于研究 CBF 的调节剂,特别是可用于筛选具有增强 CBF 能力并可能修复纤毛动力障碍摆动模式的新型药物。